Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02831491
Title A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

lung non-small cell carcinoma

Therapies

Docetaxel + Ramucirumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.